英国纽卡斯尔大学Sophie Hambleton团队研究了炎症性肠病与中和抗白细胞介素-10自身抗体的相关性。2024年8月1日出版的《新英格兰医学杂志》发表了这项成果。

研究组在一名患有婴儿期炎症性肠病（IBD）的儿童中发现了针对白细胞介素-10的高滴度中和自身抗体，这是一种先天性白细胞介蛋白-10信号传导缺陷的表型。在B细胞耗竭治疗和相关的抗白细胞介素-10滴度降低后，可停止常规IBD治疗。第二个患有中和抗白细胞介素-10自身抗体的孩子患有较轻的IBD，并且在没有B细胞耗竭的情况下接受了治疗。

研究组得出结论，中和抗白细胞介素-10自身抗体可能是IBD的致病或修正因素，对治疗具有潜在意义。

附：英文原文

Title: Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease

Author: Helen Griffin, Lourdes Ceron-Gutierrez, Nima Gharahdaghi, Soraya Ebrahimi, Sophie Davies, Peh Sun Loo, Andras Szabo, Eleri Williams, Anirban Mukhopadhyay, Louise McLoughlin, Steven Irwin, Simon Travis, Paul Klenerman, Su Bunn, Andrew J. Cant, Sophie Hambleton, Holm H. Uhlig, Rainer Doffinger

Issue&Volume: 2024-08-01

Abstract: We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling. After B-cell–depletion therapy and an associated decrease in the anti–interleukin-10 titer, conventional IBD therapy could be withdrawn. A second child with neutralizing anti–interleukin-10 autoantibodies had a milder course of IBD and has been treated without B-cell depletion. We conclude that neutralizing anti–interleukin-10 autoantibodies may be a causative or modifying factor in IBD, with potential implications for therapy.

DOI: NJ202408013910507

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2312302